Gabelli & Co Investment Advisers’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-65,689	Closed	-$663K	–	299
2022 Q4	$663K	Hold	65,689	–	–	0.14%	102
2022 Q3	$650K	Hold	65,689	–	–	0.08%	171
2022 Q2	$643K	Hold	65,689	–	–	0.08%	183
2022 Q1	$640K	Hold	65,689	–	–	0.08%	179
2021 Q4	$637K	Hold	65,689	–	–	0.08%	185
2021 Q3	$637K	Buy	+65,689	New	+$635K	0.08%	180

Gabelli & Co Investment Advisers's EBAC Position: Q1 2023 in Review

Gabelli & Co Investment Advisers sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 65,689 shares — an estimated $663K sold.

Gabelli & Co Investment Advisers first reported a position in EBAC in Q3 2021 and held it in 6 quarters. The position peaked at $663K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Gabelli & Co Investment Advisers reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 65,689 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $663K.
Gabelli & Co Investment Advisers first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Gabelli & Co Investment Advisers's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $663K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2023, filed 12 May 2023.